Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH2722 in moderate to severe atopic dermatitis
NCT05970432Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQH2722 in atopic dermatitis (AD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
TQH2722
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05970432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970432.